◎ Sugi Atlas

Atlas / Drug / Ketoprofen

Ketoprofen

drug
On this page

Also known as (rs)-ketoprofen19583RPActronActron ketoprofenAlrheumatAneolAxoridCapistenFenoket 200Hydratropic acidm-benzoyl-IDEA-033Iso-kJomethid xlKetocid 200KetonalKetoprofeneKetoprofenoKetorin

Summary

Ketoprofen (CHEMBL571) is an approved small-molecule non-steroidal anti-inflammatory drug (ATC M01AE53) targeting PTGS1, PTGS2, and SLC5A8; indicated across 21 conditions including rheumatic disorder and rheumatoid arthritis.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: M01AE53 (+2 more)
  • Targets: 3 (PTGS1, PTGS2, SLC5A8)
  • Indications: 21 conditions
  • Clinical trials: 103
  • Chemistry: 254.28 Da · C16H14O3

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL571
NameKetoprofen
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID3825
ChEBICHEBI:6128
ATCM01AE53, M01AE03, M02AA10
Molecular formulaC16H14O3
Molecular weight254.28
InChIKeyDKYWVDODHFEZIM-UHFFFAOYSA-N

SMILES: CC(C1=CC(=CC=C1)C(=O)C2=CC=CC=C2)C(=O)O

IUPAC name: 2-(3-benzoylphenyl)propanoic acid

ChEBI definition: An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.

Pharmacological roles (ChEBI): non-steroidal anti-inflammatory drug, antipyretic, EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor, drug allergen.

Other ChEBI roles (chemical / environmental): environmental contaminant, xenobiotic.

Also known as: (rs)-ketoprofen, 19583RP, Actron, Actron ketoprofen, Alrheumat, Aneol, Axorid, Capisten, Fenoket 200, Hydratropic acid, m-benzoyl-, IDEA-033

Parent form; salt/anhydrous children: CHEMBL341922, CHEMBL4650345

Patent coverage: 26,892 distinct patent families (103,580 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 102,006 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
PTGS1COX-1Inhibition6.480%P23219
PTGS2COX-2Inhibition6.160%P35354
SLC5A8SMCT1Inhibition3.920.2%Q8N695

Broader ChEMBL bioactivity targets: 19 (assay-derived). Sample: Microtubule-associated protein tau, Lysine-specific demethylase 4E, Survival motor neuron protein, Prelamin-A/C, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Peripheral myelin protein 22, Solute carrier family 22 member 6, Solute carrier family 22 member 6, Beta-lactamase, Solute carrier family 22 member 7.

Bioactivity

ChEMBL activities: 26 potent at pChembl ≥ 5 of 33 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
PTGS18.7IC502nMCHEMBL_ACT_25650357
PTGS18.7IC502nMCHEMBL_ACT_706892
PTGS17.85IC5014nMCHEMBL_ACT_7773997
PTGS27.58IC5026nMCHEMBL_ACT_25650358
PTGS27.58IC5026nMCHEMBL_ACT_706891
Q639217.47AC5034nMCHEMBL_ACT_25174523
P059797.46IC5035nMCHEMBL_ACT_25908876
SMN17.3Potency50.1nMCHEMBL_ACT_3867639
PTGS27.21IC5061nMCHEMBL_ACT_16410614
P059797.17IC5067nMCHEMBL_ACT_16410634
P059796.96IC50110nMCHEMBL_ACT_18666389
PTGS26.79IC50164nMCHEMBL_ACT_25908889
P792086.75IC50180nMCHEMBL_ACT_18666375
LMNA6.5Potency316.2nMCHEMBL_ACT_3622971
PTGS16.48IC50330nMCHEMBL_ACT_2242266
O359566.3IC50500nMCHEMBL_ACT_11000879
PTGS26.16IC50690nMCHEMBL_ACT_2242268
PTGS26.11IC50785nMCHEMBL_ACT_7773999
P059796.1IC50800nMCHEMBL_ACT_15095826
SLC22A65.89IC501300nMCHEMBL_ACT_11000914
SLC22A65.85IC501400nMCHEMBL_ACT_11000919
Q5RLM25.74Ki1840nMCHEMBL_ACT_11002337
P008115.45Potency3548nMCHEMBL_ACT_4663871
PTGS25.42IC503800nMCHEMBL_ACT_15095840
MAPT5.4Potency3981nMCHEMBL_ACT_4012320
MAPK15.05Potency8912nMCHEMBL_ACT_4717573

Target pathways

Aggregated over 3 target gene(s): PTGS1, PTGS2, SLC5A8.

Top Reactome pathways

19 total, by targets touching each:

PathwayTargetsGenes
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)2PTGS1, PTGS2
COX reactions1PTGS1
Metabolism1SLC5A8
Nicotinate metabolism1SLC5A8
Metabolism of water-soluble vitamins and cofactors1SLC5A8
Metabolism of vitamins and cofactors1SLC5A8
R-HSA-1972641SLC5A8
Synthesis of 15-eicosatetraenoic acid derivatives1PTGS2
Transport of small molecules1SLC5A8
R-HSA-4253931SLC5A8
SLC-mediated transmembrane transport1SLC5A8
Organic anion transport by SLC5/17/25 transporters1SLC5A8
Interleukin-10 signaling1PTGS2
Interleukin-4 and Interleukin-13 signaling1PTGS2
Biosynthesis of DHA-derived SPMs1PTGS2
Biosynthesis of EPA-derived SPMs1PTGS2
Biosynthesis of DPAn-3 SPMs1PTGS2
Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives1PTGS2
SLC-mediated transport of inorganic anions1SLC5A8

Dominant GO biological processes

GO termTargets
prostaglandin biosynthetic process2
response to oxidative stress2
regulation of blood pressure2
cyclooxygenase pathway2
regulation of cell population proliferation2
long-chain fatty acid biosynthetic process2
lipid metabolic process2
fatty acid metabolic process2
fatty acid biosynthetic process2
prostaglandin metabolic process2
prostanoid biosynthetic process2
cellular oxidant detoxification2
embryo implantation1
response to nematode1
response to selenium ion1

Indications & clinical

Indications

21 indications (7 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
rheumatic disorder4MONDO:0005554EFO:0005755
rheumatoid arthritis4MONDO:0008383EFO:0000685
osteoarthritis4MONDO:0005178MONDO:0005178
osteoarthritis, knee3MONDO:0005416EFO:0004616
injury3MONDO:0021178EFO:0000546
disease of the tendon3MONDO:0100010MONDO:0004857
bursitis3MONDO:0002471MONDO:0002471
migraine disorder3MONDO:0005277MONDO:0005277
periodontitis2MONDO:0005076EFO:0000649
reproductive system disorder2MONDO:0005039EFO:0000512
multiple sclerosis2MONDO:0005301MONDO:0005301
nephrolithiasis1MONDO:0008171EFO:0004253

9 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 103.

Phase distribution

PhaseTrials
PHASE442
PHASE325
Not specified19
PHASE29
PHASE15
PHASE2/PHASE33

Top trials by phase / activity

NCTPhaseStatusTitle
NCT07176572PHASE4NOT_YET_RECRUITINGAnalgesic Efficacy of Transcutaneous Electrical Nerve Stimulation and Dexketoprofen in Renal Colic
NCT00553605PHASE4COMPLETEDEfficacy And Safety Of Parecoxib 40mg vs. Ketoprofen 100mg In The Management Of Acute Renal Colic
NCT00799838PHASE4TERMINATEDEvaluation of Inflammatory Symptoms Reduction With Amoxicillin + Ketoprofen in Acute Pharyngeal Tonsillitis in Pediatric Patients
NCT01422291PHASE4COMPLETEDIV Paracetamol, Dexketoprofen or Morphine for the Treatment of Low Back Pain
NCT01558622PHASE4UNKNOWNIntraoperative Use of Dexketoprofen Trometamol, Pethidine Hcl, Tramadol Hcl and Their Combinations for Postoperative Pain Management in Laparoscopic Nissen Fundoplication
NCT01566253PHASE4COMPLETEDOral Self Medication Versus IV Administration of Pain Killers After Caesarian Delivery
NCT01685658PHASE4WITHDRAWNIntravenous Paracetamol Versus Ketoprofen When Treating Renal Colic in Emergency Situations
NCT01730326PHASE4COMPLETEDIntravenous Dexketoprofen and Paracetamol in the Treatment of Headache Caused by Acute Migraine Attack
NCT01816334PHASE4COMPLETEDSafety and Efficacy of Nonsteroidal Antiinflammatory (NSAI)Drug and Glucocorticoids in Acute Sciatica
NCT01882530PHASE4TERMINATEDNon-opioid Analgesic Combination With Morphine for Postoperative Analgesia.
NCT02018601PHASE4UNKNOWNIntercostal Nerves Block in the Midaxillary Line Versus Paravertebral Block for no Reconstructive Breast Surgery
NCT02086097PHASE4COMPLETEDDexketoprofen Trometamol in Postoperative Endodontic Pain
NCT02092012PHASE4UNKNOWNComparison of Preemptive Analgesic Effects of Dexketoprofen Versus Dexmedetomidine on Abdominal Hysterectomy Patients
NCT02159547PHASE4COMPLETEDIV Dexketoprofen vs Placebo in Migranie Attack
NCT02160236PHASE4UNKNOWNComparison of Postoperative Analgesic Efficacy of Intravenous Dexketoprofen Trometamol With Tenoxicam
NCT02238340PHASE4COMPLETEDOxycodone Extended-release in the Treatment of Perioperative Pain in Patients Undergoing Orthopaedic Surgery
NCT02248493PHASE4COMPLETEDIntravenous Paracetamol for Postoperative Pain
NCT02257970PHASE4COMPLETEDLymphedema Study for Arm or Leg Lymphedema
NCT02285972PHASE4COMPLETEDEfficacy of Intravenous Dexketoprofen and Tenoxicam on Propofol Associated Injection Pain
NCT02373514PHASE4UNKNOWNIV Paracetamol Versus IV Dexketoprofen in Dysmenorrhea
NCT02380001PHASE4COMPLETEDAnalgesic Preoperative/Postoperative Dexketoprofen Trometamol in Third Molar Surgery
NCT02491736PHASE4UNKNOWNKetoprofen Gel vs Placebo in Children With Ankle Sprain
NCT02491879PHASE4UNKNOWNKetoprofen Gel vs Placebo in Low Back Pain
NCT02568735PHASE4COMPLETEDDexketoprofen and Etoricoxib in Patients Undergoing Hip Arthroplasty
NCT02638831PHASE4COMPLETEDKetorol Gel in Gonarthrosis and Low Back Pain
NCT02730026PHASE4COMPLETEDComparison of the Clinical Efficacy of Ketoprofen, Associated or Not With Omeprazole in Lower Third Molar Removal
NCT02804126PHASE4COMPLETEDComparison of Two Pain-treatment Techniques After Cesarean Section
NCT02929147PHASE4UNKNOWNComparison of Efficacy and Safety of the Postoperative Analgesia Methods
NCT03107338PHASE4COMPLETEDPreventive Treatment of Pain After Dental Implant Surgery
NCT03122314PHASE4COMPLETEDComparison of Efficacy of Intravenous Paracetamol and Dexketoprofen for Acute Nontraumatic Musculoskeletal Pain
NCT03244540PHASE4COMPLETEDRegional Analgesia After Cesarean Section
NCT03404908PHASE4COMPLETEDTAP vs QLB in Patients After Cesarean Delivery
NCT03428503PHASE4COMPLETEDComparison of Efficacy of Intravenous Paracetamol and Dexketoprofen for Acute Traumatic Musculoskeletal Pain
NCT03768882PHASE4COMPLETEDComparison of the Efficacy of Intravenous Dexketoprofen and Paracetamol in the Treatment of Sore Throat
NCT04200885PHASE4COMPLETEDIs Therapeutic Elastic Bandage As Effective As Corticosteroids Following Third Molar Surgery?
NCT04372264PHASE4UNKNOWNIntravenous Paracetamol, Dexketoprofen and Ibuprofen in the Treatment of Acute Migraine Attack Headache
NCT04533568PHASE4COMPLETEDIbuprofen in Migraine Patients
NCT04609254PHASE4COMPLETEDParacetamol, Dexketoprofen and Ibuprofen In Non-Traumatic Acute Low Back Pain
NCT06060236PHASE4UNKNOWNDexketoprofen and Ibuprofen in Long Bone Fractures
NCT06558916PHASE4COMPLETEDComparison of the Analgesic Efficacy of Dexketoprofen Trometamol, Meperidine, and Paracetamol in Renal Colic

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 3 clinical and 16 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

407 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
FENOPROFENChEMBL + PubChemPhase 4 (approved)PTGS1, SLC5A8
3,3’,4’,5-TETRACHLOROSALICYLANILIDEChEMBLPhase 4 (approved)PTGS1, PTGS2
ACEMETACINChEMBLPhase 4 (approved)PTGS1, PTGS2
ASPIRINChEMBLPhase 4 (approved)PTGS1, PTGS2
BROMFENACChEMBLPhase 4 (approved)PTGS1, PTGS2
CAPSAICINChEMBLPhase 4 (approved)PTGS1, PTGS2
CAPTOPRILChEMBLPhase 4 (approved)PTGS1, PTGS2
CARPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
CELECOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
CIANIDANOLChEMBLPhase 4 (approved)PTGS1, PTGS2
DEXIBUPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
DEXKETOPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
DICLOFENACChEMBLPhase 4 (approved)PTGS1, PTGS2
DIETHYLSTILBESTROLChEMBLPhase 4 (approved)PTGS1, PTGS2
DOXORUBICINChEMBLPhase 4 (approved)PTGS1, PTGS2
ESFLURBIPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
ETODOLACChEMBLPhase 4 (approved)PTGS1, PTGS2
ETORICOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
FLURBIPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
GLAFENINEChEMBLPhase 4 (approved)PTGS1, PTGS2
HEXACHLOROPHENEChEMBLPhase 4 (approved)PTGS1, PTGS2
IBUPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
INDOMETHACINChEMBLPhase 4 (approved)PTGS1, PTGS2
KETOROLACChEMBLPhase 4 (approved)PTGS1, PTGS2
LEVODOPAChEMBLPhase 4 (approved)PTGS1, PTGS2
LOXOPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
LUMIRACOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
MECLOFENAMIC ACIDChEMBLPhase 4 (approved)PTGS1, PTGS2
MEFENAMIC ACIDChEMBLPhase 4 (approved)PTGS1, PTGS2
MELOXICAMChEMBLPhase 4 (approved)PTGS1, PTGS2
MOFEZOLACChEMBLPhase 4 (approved)PTGS1, PTGS2
MONOBENZONEChEMBLPhase 4 (approved)PTGS1, PTGS2
NAPROXENChEMBLPhase 4 (approved)PTGS1, PTGS2
NIMESULIDEChEMBLPhase 4 (approved)PTGS1, PTGS2
OMADACYCLINEChEMBLPhase 4 (approved)PTGS1, PTGS2
OXAPROZINChEMBLPhase 4 (approved)PTGS1, PTGS2
PIROXICAMChEMBLPhase 4 (approved)PTGS1, PTGS2
PRIMAQUINEChEMBLPhase 4 (approved)PTGS1, PTGS2
RANITIDINEChEMBLPhase 4 (approved)PTGS1, PTGS2
ROFECOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
SELINEXORChEMBLPhase 4 (approved)PTGS1, PTGS2
SUPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
TEGASERODChEMBLPhase 4 (approved)PTGS1, PTGS2
TELOTRISTATChEMBLPhase 4 (approved)PTGS1, PTGS2
TOLMETINChEMBLPhase 4 (approved)PTGS1, PTGS2
TROGLITAZONEChEMBLPhase 4 (approved)PTGS1, PTGS2
VALDECOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
VORTIOXETINEChEMBLPhase 4 (approved)PTGS1, PTGS2
CURCUMINChEMBLPhase 3PTGS1, PTGS2
RESVERATROLChEMBLPhase 3PTGS1, PTGS2
CIMICOXIBChEMBLPhase 2PTGS1, PTGS2
DERACOXIBChEMBLPhase 2PTGS1, PTGS2
ENOFELASTChEMBLPhase 2PTGS1, PTGS2
FIROCOXIBChEMBLPhase 2PTGS1, PTGS2
FLUFENAMIC ACIDChEMBLPhase 2PTGS1, PTGS2
LICOFELONEChEMBLPhase 2PTGS1, PTGS2
MAVACOXIBChEMBLPhase 2PTGS1, PTGS2
MIROPROFENChEMBLPhase 2PTGS1, PTGS2
NIFLUMIC ACIDChEMBLPhase 2PTGS1, PTGS2
PHENOTHIAZINEChEMBLPhase 2PTGS1, PTGS2

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot